ANAHEIM, CA, April 27, 2022 (WORLD NEWSWIRE)– by means of NewMediaWire– BioCorRx Inc. (OTCQB: BICX) (the “Business”), a designer and provider of ingenious treatment programs for substance abuse and associated disorders, today revealed that it has actually started the recruiting and registration process for its very first-in- human clinical trial of BICX104, an implantable eco-friendly naltrexone pellet for the treatment of opioid use disorder (OUD), which is being established under BioCorRx Pharmaceuticals, Inc., the Business’s controlled R&D subsidiary.
The BICX104 clinical research study is a Stage 1, open-label, single-center research study in 2 parallel groups of randomized healthy volunteers to assess the pharmacokinetics and security of BICX104 implantable subcutaneous naltrexone pellets and the marketed when a month intramuscular depot naltrexone injection. The research study will be led by Dr. Joel M. Neutel M.D., Director of Research Study at the Orange County Proving Ground (OCRC), situated in Tustin, CA. Interested individuals can connect straight to OCRC on their site listed below. Information about the research study can likewise be discovered at www.clinicaltrials.gov under NCT number 04828694.
” This is an incredibly essential turning point as it marks the next stage of advancement for BICX104,” stated Brady Granier, President, Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc. “This research study will help assess the pharmacokinetics and security of BICX104 compared to another marketed naltrexone item. Our company believe that much better compliance to naltrexone therapy will eventually lead to much better patient results. We aim to register all topics as quickly as possible and look forward to supplying development updates as they appear.”
BICX104 is being established in partnership with the National Institute on Substance Abuse (NIDA), part of the National Institutes of Health (NIH), under RFA DA-19-002, “ Advancement of Medications to Prevent and Reward Opioid Use Disorders and Overdose (UG3/UH3) (Clinical Trial Optional)” The Business has an active Investigational New Drug (IND) status, and the FDA has actually considered the 505( b)( 2) shortened path appropriate, also the chance to seek ultimate dual indicator on the item for OUD and Alcohol Use Disorder (AUD).
About Orange County Proving Ground (OCRC)
OCRC is a therapeutically-focused early and late phase clinical advancement website providing a 50+ bed PK system and a Stage II-IV center. Registering, handling and carrying out cutting edge clinical research study procedures for big pharmaceutical and mid-sized biotechnical business, OCRC has actually turned into a premier, patient- focused provider offering therapeutic proficiency throughout an remarkable therapeutic spectrum consisting of however not minimal to Heart Disease, Dermatology, Diabetes, High Blood Pressure, Liver Illness, Nephrology and Injury Recovery.
For more information, please go to www.ocresearchcenter.com
About BioCorRx
BioCorRx Inc. (OTCQB: BICX) is an addiction treatment services business providing a distinct approach to the treatment of substance use and other associateddisorders Beat Addiction Recovery is a substance use disorder recovery program that generally consists of BioCorRx’s exclusive Cognitive Behavioral Therapy (CBT) modules along with peer assistance by means of mobile app along with medication recommended by an independent treating doctor under their discretion. The UnCraveRx ® Weight-loss Program is likewise a medication assisted weight-loss program that consists of gain access to to concierge on- need health experts: nutritional experts, physical fitness professionals and individual assistance from behavioral professionals; please go to www.uncraverx.com for more information on UnCraveRx ®. The Business likewise manages BioCorRx Pharmaceuticals, a clinical phase drug advancement subsidiary presently looking for FDA approval for BICX104, an implantable naltrexone pelletfor treatment of alcohol and opioid use disorders For more information on BICX and its subsidiary pipeline, please go to www.BioCorRx com
BioCorRx Inc.
.
financiers @
BioCorRx com
. 714-462-4880
Financier Relations:(
*)
. Crescendo Communications, LLC
. 212- 671-1020 x304
. bicx@crescendo-ir.com
Media Contact
PhillComm Worldwide
@PhillComm. Worldwide
BioCorRx 704-942-1557
.